Andrew Allen
Andrew Allen, M.D., Ph.D. is a physician-scientist and biotechnology entrepreneur who has played a role in the development of multiple oncology therapeutics.
Early life and education
Allen trained in medicine at the University of Oxford and earned a Ph.D. in immunology from Imperial College London.[1][2]
Career
Allen began his biotechnology career in oncology drug development roles at Abbott Laboratories and Chiron Corporation. In 2006 he joined Pharmion Corporation as Chief Medical Officer, where he helped lead the clinical development of Azacitidine, a DNA methylation inhibitor used for the treatment of myelodysplastic syndromes.[3]
In 2009, Allen co-founded Clovis Oncology, where he served as Chief Medical Officer until 2015. During his tenure, the company developed Rucaparib, a PARP inhibitor later approved for ovarian and prostate cancers.[4][5]
In 2015, Allen co-founded Gritstone bio and served as chief executive officer, which developed neoantigen vaccines.[1]
Allen has also served on the boards of multiple biotechnology companies.[1]
Scientific contributions
Allen has contributed to the development of targeted therapies and personalized immunotherapy approaches in oncology. Allen's scientific contributions include advancing the translational science of neoantigen vaccines. In 2024, he co-authored a study in Nature Medicine analyzing samples from a Gritstone-led clinical trial, which revealed an unexpected hierarchy of neoantigen immunodominance in which T-cell responses preferentially focused on TP53-derived epitopes at the expense of clinically relevant KRAS neoantigens.[6] The study demonstrated how dominant epitopes within a multi-epitope construct can suppress immune responses to other encoded targets, helping establish broader principles of antigen competition in therapeutic cancer vaccines.
References
- ↑ 1.0 1.1 1.2 "Andrew Allen, MD, PhD, President & CEO, Gritstone bio". PMWC Precision Medicine World Conference.
- ↑ "Andrew R. Allen, Co-Founder, President, Chief Executive Officer - eMedEvents". www.emedevents.com. Retrieved 2026-04-10.
- ↑ Silverman, Lewis R. (2002). "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B". Journal of Clinical Oncology. doi:10.1200/JCO.2002.04.117. PMID 12011120.
- ↑ "FDA approves rucaparib for ovarian cancer". U.S. Food and Drug Administration.
- ↑ "Rucaparib monotherapy in patients with BRCA-mutated ovarian cancer". Lancet Oncology. 2016. doi:10.1016/S1470-2045(16)30559-9. PMID 27908594.
- ↑ Rappaport, A. R. (2024). "A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results". Nature Medicine. doi:10.1038/s41591-024-02851-9. PMID 38538867 Check
|pmid=value (help).
This article "Andrew Allen" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Andrew Allen. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
